Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis

Author： Seret Guillaume   Hanrotel Catherine   Bendaoud Boutahar   Le Meur Yannick   Renaudineau Yves  

Publisher： Oxford University Press

ISSN： 2048-8505

Source： Clinical Kidney Journal, Vol.6, Iss.1, 2013-02, pp. : 74-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab: B-cell depletion therapy for the treatment of rheumatoid arthritis

By Dass Shouvik   Vital Edward M   Emery Paul  

Future Rheumatology, Vol. 1, Iss. 3, 2006-06 ,pp. : 293-302

Future Medicine

Access to resources Recommend Favorite

Review of refractory lupus nephritis

By Habibi Shabina  

International Journal of Clinical Rheumatology, Vol. 8, Iss. 1, 2013-02 ,pp. : 61-72

Future Medicine

Access to resources Recommend Favorite

Role of the Fcγγ receptor IIIA-V/F158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis

By Li L-H   Yuan H   Pan H-F   Li W-X   Li X-P   Ye D-Q  

Scandinavian Journal of Rheumatology, Vol. 39, Iss. 2, 2010-03 ,pp. : 148-154

Informa Healthcare

Access to resources Recommend Favorite

Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis

By Hayat Sawsan   Uppal Sukhbir   Narayanan Nampoory M.   Johny Kaivilayil   Gupta Ramkumar   Al-Oun Mohammed  

Clinical Rheumatology, Vol. 26, Iss. 6, 2007-06 ,pp. : 973-975

Springer Publishing Company

Access to resources Recommend Favorite

Erratum to: Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

By Karino Yoshiyasu  

Hepatology International, Vol. 4, Iss. 4, 2010-12 ,pp. : 789-790

Springer Publishing Company

Access to resources Recommend Favorite